Krystal Biotech (KRYS) Other financing activities (2023 - 2026)

Krystal Biotech (KRYS) has 4 years of Other financing activities data on file, last reported at $6.5 million in Q1 2026.

• For the quarter ending Q1 2026, Other financing activities rose 344.66% year-over-year to $6.5 million; the trailing twelve-month figure through Mar 2026 stood at $27.7 million (up 54.81% YoY), and the FY2025 full-year result was $22.7 million, down 30.06% from the prior year.
• Other financing activities retreated to $6.5 million in Q1 2026, from $15.7 million in the prior quarter.
• In the past five years, Other financing activities ranged from a high of $25.4 million in Q2 2023 to a low of $1.5 million in Q1 2025.
• A 4-year average of $8.1 million and a median of $3.7 million in 2025 frame the typical range for Other financing activities.
• Across the five-year window, Other financing activities soared 618.35% in 2024 and slumped 90.84% in 2025, its largest moves.
• Tracing KRYS's Other financing activities over 4 years: stood at $2.6 million in 2023, then dropped by 6.94% to $2.4 million in 2024, then soared by 546.17% to $15.7 million in 2025, then slumped by 58.56% to $6.5 million in 2026.
• Business Quant data shows KRYS's Other financing activities at $6.5 million in Q1 2026, $15.7 million in Q4 2025, and $3.7 million in Q3 2025.